No Data
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Nuotai Biology (688076.SH) distributed 0.1 yuan per share in the first half of the year, with a record date of September 9th.
Nutai Biological (688076.SH) announced that the company will distribute interim equity in the first half of 2024, with a dividend of per share...
Jiangsu Sinopep-Allsino Biopharmaceutical's H1 Profit Surges Fivefold
Jiangsu Sinopep-Allsino Biopharmaceutical: Summary of Half-Year Report in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Half-year report for the year 2024.
Nuo Tai Biotech (688076.SH): Passed the pharmaceutical GMP compliance inspection.
On August 16th, Gelunhui reported that Notai Biology (688076.SH) recently received the "Certificate of Export of Active Pharmaceutical Ingredient to the European Union" and the "Notice of Conformity of GMP Inspection of Drugs" issued by Jiangsu Provincial Drug Administration, and the production lines of raw materials (liraglutide, only for processing documents for export to the European Union) in workshop 106 of the Lianyungang factory, production lines of raw materials (exenatide) in workshop 106, and production lines of raw materials (acetic acid sucrose) in workshop 101, have been inspected on site by the Jiangsu Provincial Drug Administration, and met the requirements of the "Drug Production Quality Management Standard".
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%No Data
No Data
